Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in children with non-diabetic proteinuria
IRCT20220405054414N1Phase 2Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of empagliflozin in proteinuria, sponsored by Iran University of Medical Sciences. Primary endpoints: Safety and tolerability and Change in renal function. Started Apr 2023; status: completed.
02
Drugs
empagliflozin
03
Conditions
proteinuria
Beyond the preview
Go deeper on IRCT20220405054414N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220405054414N1.